Monoclonal antibodies for migraine prevention: hope, hype, and health economy challenge
- PMID: 32732219
- PMCID: PMC7384840
- DOI: 10.3399/bjgp20X711833
Monoclonal antibodies for migraine prevention: hope, hype, and health economy challenge
References
-
- Steiner TJ, Scher AI, Stewart WF, et al. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia. 2003;23(7):519–527. - PubMed
-
- GBD 2016 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–1259. - PMC - PubMed
-
- Manack AN, Buse DC, Lipton RB. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep. 2011;15(1):70–78. - PubMed
-
- National Institute for Health and Care Excellence Headaches in over 12s: diagnosis and management CG150. 2015 https://www.nice.org.uk/guidance/cg150 (accessed 1 Jun 2020).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical